NCT04050436 |
|
Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer
|
View
|
NCT02786381 |
|
Idylla IFV-RSV Panel Clinical Testing
|
View
|
NCT03063021 |
|
The FIGHT-RP1 Study
|
View
|
NCT06590480 |
|
An Expanded Access Program for VO RP1 in Combination With Nivolumab in Patients With Advanced Melanoma
|
View
|
NCT04349436 |
|
A Phase 1B2 Study of RP1 in Solid Organ Transplant Patients With Advanced Cutaneous Malignancies
|
View
|
NCT02709876 |
|
Autologous Bone Marrow-Derived CD34 CD133 and CD271 Stem Cell Transplantation for Retinitis Pigmentosa
|
View
|
NCT04776889 |
|
The Prognosis of Lipid Reprogramming With Rosuvastatin in Castrated Egyptian Prostate Cancer Patients
|
View
|
NCT03767348 |
|
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab
|
View
|
NCT05858229 |
|
Neo-adjuvant Treatment for Squamous Cell Carcinoma Using Direct Tumor Injection With RP1
|
View
|
NCT06067061 |
|
neoBREASTIM Atezolizumab Plus RP1 Oncolytic Immunotherapy in the NeoAdjuvant Setting of Triple-Negative Breast Cancer
|
View
|
NCT06216938 |
|
RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis
|
View
|
NCT06264180 |
|
VO and Nivolumab vs Physicians Choice in Advanced Melanoma That Progressed on Anti-PD-1 Anti-CTLA-4 Drugs IGNYTE-3
|
View
|
NCT04092023 |
|
Self-care Management Programme for Type 2 Adult DM Patients With Poor Glycemic Control
|
View
|